Yan, Chenggong
Wang, Lingfeng
Lin, Jie
Xu, Jun
Zhang, Tianjing
Qi, Jin
Li, Xiangying
Ni, Wei
Wu, Guangyao
Huang, Jianbin
Xu, Yikai
Woodruff, Henry C.
Lambin, Philippe
Article History
Received: 20 June 2021
Revised: 26 August 2021
Accepted: 27 September 2021
First Online: 29 November 2021
Declarations
:
: The scientific guarantor of this publication is Prof. Yikai Xu.
: Philippe Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian Medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures, and DualTpharma. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in-kind manpower contribution from Oncoradiomics, BHV, Merck, and Convert Pharmaceuticals. PL owns shares in Oncoradiomics SA and Convert Pharmaceuticals SA and is a co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issued patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable inventions (software) licensed to ptTheragnostic/ DNAmito, Oncoradiomics, and Health Innovation Ventures. HW owns (minority) shares in Oncoradiomics. Lingfeng Wang, Tianjing Zhang, and Wei Ni have associations with Philips Healthcare, and each provided technical support for DL programming. None of the authors had control of the data that might present a conflict of interest for the other employee or consultant authors.
: One of the authors has significant statistical expertise.
: Written informed consent was waived by the institutional review board.
: Institutional review board approval was obtained.
: • retrospective• diagnostic or prognostic study• multicenter study
Free to read: This content has been made available to all.